COSCIENS Biopharma Inc.

CSCINASDAQHealthcare

$2.72

+$0.00(+0.00%)

Market Cap$8572175

P/E Ratio—

52W High$4.6054

52W Low$1.75

Avg Volume10K

Open$2.72

Beta1.85

Net Income Financials Revenue

COSCIENS Biopharma Inc. (CSCI) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CSCI · net income · updated Jun 9, 2026

Core profitability metrics

CSCI · net income · margin · TTM · CAGR

Net income was −$15.3M for FY2024 (fiscal year ending 2024-12-31), down 339.3% year-over-year. Net profit margin was -111.1%. Based on available data, COSCIENS Biopharma Inc. has been profitable since at least 2010.

FY2024 Net Income−$15.3M▼ -339.3% YoY

Trailing 12M (TTM)−$18.8Mtrailing 4 quarters sum

Net Profit Margin-111.1%−$15.3M ÷ $13.8M

YoY Change-339.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2010

▸ FMP /income-statement · Annual · CSCI net income history · CSCI profit margin

Annual net income data

CSCI · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2024Loss−$15.3M▼ 339.3%-111.1%$13.8M

FY2023Loss−$3.5M▼ 201.1%-48.8%$7.1M

FY2022$3.4M▲ +30.6%23.7%$14.6M

FY2021$2.6M▲ +81.3%19.6%$13.5M

FY2020$1.5M▲ +267.9%12.3%$11.9M

Net income vs peers (Healthcare)

CSCI vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

COSCIENS Biopharma Inc.YOU

CSCI

−$15.3M-339.3%-111.1%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

COSCIENS Biopharma Inc. (CSCI) reported net income of −$15.3M for FY2024 (fiscal year ending 2024-12-31), down 339.3% year-over-year. The net profit margin was -111.1% — meaning the company kept $-1.11 of every dollar of revenue as profit.

Based on available data, COSCIENS Biopharma Inc. has been profitable since at least 2010. Net income reached a peak of $3.5M in FY2015. Data available for 15 fiscal years.

COSCIENS Biopharma Inc.'s net profit margin was -111.1% for FY2024, based on the latest annual results.

Investors sometimes search for "COSCIENS Biopharma Inc. net worth" — the company's market capitalization is a separate figure from CSCI net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CSCI net income · 4 questions

COSCIENS Biopharma Inc. is not currently profitable on an annual basis. The company reported a net loss of $15.3M for FY2024.

is CSCI profitabledoes CSCI make a profitCSCI profitabilityCSCI profitable company

▸ Source: FMP /income-statement · GAAP · COSCIENS Biopharma Inc. · COSCIENS Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026